Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00445068
• Other study ID #: CLBH589B2203
• Status: Terminated
• Phase: Phase 2
• Start date: April 16, 2007
• Est. completion date: December 25, 2009

Study information

• Verified date: June 2021
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy. Patients must have received in prior therapy either bortezomib or lenalidomide

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 38
• Est. completion date: December 25, 2009
• Est. primary completion date: May 19, 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Adults = 18 years old

2. Subjects must have signed the consent form before undergoing any study specific screening procedures and before participation in this study. The subject must be fully informed by the investigator of the nature and potential risks of participation in this study.

3. Patients must have had a diagnosis of symptomatic multiple myeloma (from IMWG see (Kyle et al,2003) meeting all three of the following criteria:

• Monoclonal immunoglobulin (spike on electrophoresis, or band on immunofixation) on serum or on 24 hour urine.

• Bone marrow (clonal) plasma cells or plasmacytoma

• Related organ or tissue impairment (anemia, hypercalcemia, lytic bone lesions, renal insufficiency, hyperviscosity or recurrent infections) (The Kyle et al 2003 definition of symptomatic Myeloma has been adapted based on the new exclusion criteria defined in protocol amendment 1)

4. Subjects must have received at least two prior lines of therapy and be refractory to the most recent line of therapy according to the following definitions: Refractory to most recent line of therapy Defined by disease progression during treatment or within 60 - 100 days after the completion of the most recent line of therapy. This includes the development of disease progression during maintenance or consolidation therapy with high dose glucocorticoids, or any other specific MM therapy Sixty days is counted from the point in time when the first response assessment is performed after completion of the last line of therapy. At a maximum, disease progression should be documented within 100 days after the last day of the last dose of any anti-MM therapy, including if last regimen of the most recent line of therapy was Autologous Stem Cell Transplant (ASCT). Stable disease patients also part of the IMWG definition are not eligible for this trial. At study screening, Progressive Disease (PD) will be assessed by comparing screening values or symptoms in reference to the baseline (values or symptoms) of their last line of therapy. Should a patient have experienced an initial response on their last line of therapy, PD should be assessed in reference to the lowest values of the initial confirmed response Minimal Response(MR) / Partial Response (PR) / Complete Response (CR).

Disease progression is defined by having one or more of the following:

• >25% increase in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation.

• >25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation.

• >25% increase in plasma cells in a bone marrow aspirate or on bone marrow biopsy, which must also be an absolute increase of at least 10%

• Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.

• Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).

• Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).

5. Subjects must have previously been treated with bortezomib and at least one of the following: lenalidomide or thalidomide

6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2

7. Patients must have the following hematological laboratory values:

• Absolute Neutrophil Count (ANC) = 1.5 x 109/L (or =1.0 x 109/L if the neutropenia is clinically related to progressive myeloma with bone marrow infiltration of > 50% involvement

• Hemoglobin = 8.0 g/dl

• Platelets = 75.0 x 109/L (or = 50.0 x 109/L x if the thrombocytopenia is clinically related to progressive myeloma with bone marrow infiltration > 50% involvement

8. Patients must have the following renal function as shown by :

• Calculated Creatinine Clearance (CrCL) > 30ml/min (Cockcroft and Gault formula)

9. Patients must have adequate liver function as shown by:

• Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) = 2.5 x Upper limit of normal (ULN)

• Serum bilirubin = 1.5 x ULN

• Albumin = 2.5 g/dl

10. Patients must have the following non-hematological laboratory values:

• Serum potassium = Lower Limit of Normal (LLN),

• Total serum calcium [corrected for serum albumin] or ionized calcium =LLN,

• Serum magnesium = LLN

• Serum phosphorus = LLN

• Normal thyroid function (TSH and free T4) (hypothyroidism correctable with supplements is allowed)

11. Baseline Multiple Uptake Gated Acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate Left Ventricular Ejection Fraction (LVEF) = the lower limit of the institutional normal

12. Patients must be willing and able to undergo bone marrow aspirates as per protocol, with/without bone marrow biopsy according to their center's practice. The bone marrow aspirate /biopsy must be adequate to allow for comparison for the later efficacy response assessments.

13. Patients must have an M component at baseline above a minimum threshold of: 1g/dl (10g/L) for serum M component, or 200mg/24h urine M component.

Exclusion criteria:

1. Prior therapy with an Histone Deacetylase (HDAC) inhibitor for the treatment of Multiple Myeloma (MM)

2. Patients with non-secretory MM

3. Patients who have received allogenic stem cell transplantation < 12 months prior to study

4. Patients who have had prior allogenic stem cell transplantation and show evidence of active graft versus-host disease that requires immunosuppressive therapy

5. Patients with amyloidosis

6. Patients with peripheral neuropathy > grade 2

7. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

• Patients with congenital long QT syndrome

• History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but should be discussed with the Sponsor prior to enrollment)

• Any history of ventricular fibrillation or torsade de pointes

• Bradycardia defined as Heart Rate (HR)< 50 bpm. Patients with pacemakers are eligible if HR = 50 bpm.

• Screening Electrocardiogram (ECG) with a corrected QT interval (QTc) > 450 msec

• Right bundle branch block + left anterior hemi-block (bi-fascicular block)

• Patients with myocardial infarction or unstable angina = 6 months prior to starting study drug

8. Other clinically significant heart disease (e.g., Congestive Heart Failure (CHF NY) Heart Association class III or IV, uncontrolled hypertension, or history of poor compliance with an antihypertensive regimen)

9. Impairment of GI function or GI disease that may significantly alter the absorption of LBH589

10. Patients with unresolved diarrhea > CTCAE grade 1.

11. Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol

12. Patients using medications that have a relative risk of prolonging the QT interval or inducing torsades de pointes if the medications cannot be discontinued or switched to a different medication prior to starting study drug

13. Concomitant use of CYP3A4 inhibitors

14. Patients with an active bleeding diathesis or on any treatment with therapeutic doses of sodium warfarin (Coumadin®) or any other anti-vitamin K drug. Low doses of Coumadin® (e.g., = 2 mg/day), or low doses of any other anti-vitamin K drug, for line patency is allowable

15. Patients who have received chemotherapy, radiation therapy or any investigational drugs, bortezomib or other immunomodulatory therapy (e.g., thalidomide, lenalidomide) or immunotherapy = 3 weeks prior to starting study drug or who have not recovered from side effects of such therapy

16. Patients who have received high-dose corticosteroids as the only component of their most recent line of therapy

17. Patients who have received steroids (e.g., dexamethasone) = 2 weeks prior to starting study treatment or who have not recovered from side effects of such therapy. Concomitant therapy medications that include corticosteroids are allowed if subjects receive < 20 mg of prednisone or equivalent as indicated for other medical conditions (and not as maintenance or an anticancer therapy for MM), or up to 100 mg of hydrocortisone as premedication for a administration of certain medications or blood products, while enrolled in this study.

18. Patients whose clinical condition would need valproic acid therapy during study or = 5 days prior to starting drug

19. Patients who have undergone major surgery = 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy

20. Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)not willing to use a double method of contraception during the study and for 3 months after treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589

21. Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and for 3 months after treatment. One of these methods of contraception must be a condom

22. Patients with a current second malignancy or a prior malignancy within the last 5 years except adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer

23. Patients with any significant history of non compliance to medical regimens or unwilling or unable to comply with the protocol or unable to grant reliable informed consent.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• LBH589

Locations

Country	Name	City	State
Germany	Novartis investigative Site	Berlin
Germany	Novartis Investigative Site	Heidelberg
Germany	Novartis Investigative Site	Kiel
Germany	Novartis Investigative Site	Starnberg
Germany	Novartis Investigative Site	Wuerzburg
United States	University of Michigan	Ann Arbor	Michigan
United States	Emory University	Atlanta	Georgia
United States	Aptium Oncology	Berkeley	California
United States	Dana Farber	Boston	Massachusetts
United States	Rush University	Chicago	Illinois
United States	University of Chicago	Chicago	Illinois
United States	Metrohealth	Cleveland	Ohio
United States	University of Texas Southwestern	Dallas	Texas
United States	Rocky Mountain Cancer Center	Denver	Colorado
United States	City of Hope	Duarte	California
United States	Duke	Durham	North Carolina
United States	Hackensack University	Hackensack	New Jersey
United States	Indiana University	Indianapolis	Indiana
United States	University of Iowa	Iowa City	Iowa
United States	Sarah Canon Research Center	Nashville	Tennessee
United States	Vanderbilt	Nashville	Tennessee
United States	Christiana Care	Newark	Delaware
United States	Washington University	Saint Louis	Missouri
United States	CTRC	San Antonio	Texas
United States	UCSF	San Francisco	California
United States	Mayo Clinic	Scottsdale	Arizona
United States	Stanford	Stanford	California
United States	Moffitt Cancer Center	Tampa	Florida
United States	Wake Forest	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate (Complete Response(CR) / Partial Response (PR))	The response (complete response (CR) / partial response (PR)) rate as per Bladé criteria was assessed by the investigator. Response to treatment was evaluated in participants with multiple myeloma (MM) who have received at least two prior lines of therapy and whose disease was refractory to the most recent line of therapy.	From Start of the Study up to 57 Weeks approximately.
Secondary	Overall Response Rate	Overall response rate is the proportion of patients with a best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria (Overall Response (OR) = CR + PR).; Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.	From Start of the Study up to 57 Weeks approximately.
Secondary	Clinical Benefit Rate	Clinical benefit rate is defined by the percentage of participants achieving either a confirmed tumor response or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A "partial response" requires a decrease of 30% or more, "Progression" requires an increase of at least 20%, and "Stable disease" falls in between these two. All responses have a repeat assessment to confirm the response	From Start of the Study up to 57 Weeks approximately.
Secondary	Duration of Response	Duration of response is defined as time between time to first documented response (CR/PR) and time to first documented disease progression or death.	From Start of the Study up to 57 Weeks approximately.
Secondary	Time to Response	Time to response is defined as time between Day 1 cycle 1 and time to first documented response (CR/PR).	From Start of the Study up to 57 Weeks approximately.
Secondary	Progression Free Survival (PFS)	Progressions free survival is defined as time between Day 1 cycle 1 and time to first documented disease progression or death. Disease progression will be determined as per response criteria.	From Start of the Study up to 57 Weeks approximately.
Secondary	Safety and Tolerability	Adverse Event (AE) are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.	From Start of the Study up to 57 Weeks approximately.
Secondary	Time to Peak Concentration (Tmax) of Panobinostat	Tmax is defined as the time at which the Cmax occurs. It will be obtained from the Tmax parameter calculated by WinNonlin®. If there is no measurable Cmax in the subject's pharmacokinetic (PK) profile, then Tmax will be missing for that subject. Tmax will be reported in units of h.	Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Secondary	Maximum Plasma Concentration (Cmax) of Panobinostat	Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations. It will be obtained from the Cmax parameter calculated by WinNonlin®. If there is no measurable concentration in the subject's PK profile, then Cmax will be missing for that subject. Cmax will be reported in units of ng/mL.	Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Secondary	Area Under the Plasma Concentration (AUC0-24) of Panobinostat	Area under the curve (AUC) is defined as the area under concentration-time curve as a measure of drug exposure. The area under the plasma concentration-time curve from time zero to 24 hours.	Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Secondary	Last Observed Plasma Concentration (Clast) of Panobinostat	Clast is defined as the Last observed (quantifiable) plasma concentration (Clast), in units of ng/mL. Blood samples were collected to assess Clast.	Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8
Secondary	Time of Clast (Tlast) of Panobinostat	Time of Clast (Tlast) will be obtained from the Tlast parameter calculated by WinNonlin®. If there is no measurable concentration in the subject's PK profile, then Tlast will be missing for that participants. Tlast will be reported in units of h.	Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8